| Latest | F'cast | |
|---|---|---|
| Div Yield | 0.0% | 0.4% |
| Div Cover | n/a | n/a |
| Op Mrgn | -22770.2% | -1401.9% |
| ROCE | n/a |
| Latest | F'cast | |
|---|---|---|
| P/E | n/a | n/a |
| PEG | n/a | n/a |
| Pr/Revenue | 2843.3 | 1306.4 |
| Pr/Book | 3.8 |
| Latest | F'cast | |
|---|---|---|
| Revenue | -48.1% | 117.6% |
| PBT | n/a | n/a |
| EPS | n/a | n/a |
| DPS | n/a | n/a |
| Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 31-Dec-07 | 0.06 | (3.34) | (4.24)p | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-08 | 0.06 | 4.86 | 6.23p | 9.1 | n/a | n/a | n/a | 0.0% |
| 31-Dec-09 | 22.05 | 9.10 | 10.46p | 9.1 | 0.1 | +68% | n/a | 0.0% |
| 31-Dec-10 | 0.03 | (2.47) | (2.44)p | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-11 | 0.02 | (3.61) | (4.12)p | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
| Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 31-Dec-12 | 0.04 | (0.51) | (0.59)p | n/a | n/a | n/a | 0.25p | 0.4% |
| 31-Dec-13 | 0.04 | (1.36) | (0.32)p | n/a | n/a | n/a | 0.50p | 0.8% |
Copyright © 2012 FactSet Research Systems Inc. All rights reserved.
| Annual General Meeting: 2012 | 23-May-2012 | 12:20 | RNS |
| Posting of Annual Report and AGM Notice | 17-Apr-2012 | 07:00 | RNS |
| Preliminary Results | 27-Mar-2012 | 07:00 | RNS |
| ImmuPharma's losses grow in 2011 | 27-Mar-2012 | ShareCast |
| SABMiller exec buys a round | 24-Jan-2012 | ShareCast |
| Immupharma posts wider losses | 05-Apr-2011 | ShareCast |
No deals were found in the last 28 days.
| Currency | UK Pounds |
| Share Price | 58.75p |
| Change Today | 0.000p |
| % Change | 0.00 % |
| 52 Week High | 99.50p |
| 52 Week Low | 57.00p |
| Volume | 3,100 |
| Shares Issued | 81.53m |
| Market Cap | £47.90m |
| Beta | 0.09 |
| RiskGrade | 161 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| Strong Buy | 2 |
| Buy | 0 |
| Neutral | 1 |
| Sell | 0 |
| Strong Sell | 1 |
| Total | 4 |

| No dividends found |
| Chair | Richard Warr |
| CEO | Dimitri Dimitriou |
You are here: research